Yearly Archives: 2006

New Allon publication shows key role of ADNP in embryo development

VANCOUVER, December 12, 2006 — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced publication of a new preclinical study demonstrating that the endogenous neuroprotective protein ADNP (Activity-Dependant Neuroprotective Protein) is essential for brain function and ... Continue reading →

Allon Therapeutics presents at IBC's EuroTIDES conference

VANCOUVER, December 7, 2006 — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, presented a case study during IBC’s EuroTIDES 2006 conference: Oligonucleotide, RNAi and Peptides for the Drug Development and Manufacturing Industry in Hamburg, Germany. The presentation, entitled “... Continue reading →

Allon receives approval for Phase II clinical trial in Alzheimer's-related condition

VANCOUVER, December 6, 2006 — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced IRB (Institutional Review Board) approval to begin enrolling patients for a Phase II human clinical trial evaluating the Company’s lead product AL-108. The trial will evaluate the effi... Continue reading →

Allon Therapeutics announces final closing of $10-million private placement

VANCOUVER, November 29, 2006 — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that it has completed the second and final closing of its recently announced private placement. The Company increased the size of this placement to $10.02 million by issuing an additi... Continue reading →

Allon Therapeutics releases third quarter operating results

VANCOUVER, November 1, 2006 — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, reported today in its third quarter 2006 operating results that it continued to achieve all of its milestones during the quarter, including the approval from Health Canada to allow the company to begi... Continue reading →

← Older posts